Literature DB >> 22354091

Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis.

Shinichi Toyooka1, Katsuyuki Kiura, Mitsuhiro Takemoto, Takahiro Oto, Nagio Takigawa, Toshiyoshi Fujiwara, Shinichiro Miyoshi, Hiroshi Date.   

Abstract

The purpose of this study was to show the long-term outcome of induction chemoradiotherapy, using docetaxel and cisplatin with concurrent radiotherapy followed by surgery for non-small-cell lung cancer (NSCLC) with mediastinal nodal metastasis. Between January 2000 and July 2006, 22 consecutive NSCLC patients with pathologically proven mediastinal nodal metastasis were treated with tri-modality therapy. The regimen consisted of docetaxel and cisplatin plus concurrent radiation at a dose of 40-46 Gy. The induction therapy was followed by surgery 4-6 weeks later. The pulmonary resections were composed of a lobectomy in 19 patients, including 3 with a sleeve lobectomy, a bilobectomy in 2 patients and a left pneumonectomy in 1 patient. With a median follow-up duration of 8.7 years, the 3-year and 7-year overall survival (OS) rates for the entire population were 72.7 and 63.6%, respectively. Our results suggest that tri-modality therapy is promising for NSCLC patients with mediastinal nodal metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22354091      PMCID: PMC3329306          DOI: 10.1093/icvts/ivs028

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  14 in total

1.  Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.

Authors:  Yoshihiko Segawa; Katsuyuki Kiura; Nagio Takigawa; Haruhito Kamei; Shingo Harita; Shunkichi Hiraki; Yoichi Watanabe; Keisuke Sugimoto; Takuo Shibayama; Toshiro Yonei; Hiroshi Ueoka; Mitsuhiro Takemoto; Susumu Kanazawa; Ichiro Takata; Naoyuki Nogami; Katsuyuki Hotta; Akio Hiraki; Masahiro Tabata; Keitaro Matsuo; Mitsune Tanimoto
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

2.  Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

Authors:  P Bonomi; K Kim; D Fairclough; D Cella; J Kugler; E Rowinsky; M Jiroutek; D Johnson
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

Review 3.  Multidisciplinary management of lung cancer.

Authors:  Alexander Spira; David S Ettinger
Journal:  N Engl J Med       Date:  2004-01-22       Impact factor: 91.245

4.  Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.

Authors:  Jan P van Meerbeeck; Gijs W P M Kramer; Paul E Y Van Schil; Catherine Legrand; Egbert F Smit; Franz Schramel; Vivianne C Tjan-Heijnen; Bonne Biesma; Channa Debruyne; Nico van Zandwijk; Ted A W Splinter; Giuseppe Giaccone
Journal:  J Natl Cancer Inst       Date:  2007-03-21       Impact factor: 13.506

5.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

6.  Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer.

Authors:  Ikuo Sekine; Hiroshi Nokihara; Minako Sumi; Nagahiro Saijo; Yutaka Nishiwaki; Satoshi Ishikura; Kiyoshi Mori; Iwao Tsukiyama; Tomohide Tamura
Journal:  J Thorac Oncol       Date:  2006-10       Impact factor: 15.609

7.  Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer.

Authors:  Hiroyasu Yokomise; Masashi Gotoh; Taku Okamoto; Yasumichi Yamamoto; Shinya Ishikawa; Takashi Nakashima; Daiki Masuya; Dage Liu; Cheng-long Huang
Journal:  J Thorac Cardiovasc Surg       Date:  2007-05       Impact factor: 5.209

8.  Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.

Authors:  K S Albain; V W Rusch; J J Crowley; T W Rice; A T Turrisi; J K Weick; V A Lonchyna; C A Presant; R J McKenna; D R Gandara
Journal:  J Clin Oncol       Date:  1995-08       Impact factor: 44.544

9.  Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer.

Authors:  H Katayama; H Ueoka; K Kiura; M Tabata; T Kozuki; M Tanimoto; T Fujiwara; N Tanaka; H Date; M Aoe; N Shimizu; M Takemoto; Y Hiraki
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

10.  Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer.

Authors:  K Kiura; H Ueoka; Y Segawa; M Tabata; H Kamei; N Takigawa; S Hiraki; Y Watanabe; A Bessho; K Eguchi; N Okimoto; S Harita; M Takemoto; Y Hiraki; M Harada; M Tanimoto
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

View more
  12 in total

1.  Is tumor location an independent prognostic factor in locally advanced non-small cell lung cancer treated with trimodality therapy?

Authors:  Kazuhiko Shien; Shinichi Toyooka; Junichi Soh; Hiromasa Yamamoto; Shinichiro Miyoshi
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

2.  Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis.

Authors:  Shinichi Toyooka; Katsuyuki Kiura; Kazuhiko Shien; Kuniaki Katsui; Katsuyuki Hotta; Susumu Kanazawa; Hiroshi Date; Shinichiro Miyoshi
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-09-12

3.  Clinical outcome of patients with recurrent non-small cell lung cancer after trimodality therapy.

Authors:  Ken Suzawa; Junichi Soh; Yuta Takahashi; Hiroki Sato; Kazuhiko Shien; Hiromasa Yamamoto; Susumu Kanazawa; Katsuyuki Kiura; Shinichiro Miyoshi; Shinichi Toyooka
Journal:  Surg Today       Date:  2019-02-08       Impact factor: 2.549

4.  Stromal PDGFR-β Expression is Associated with Postoperative Survival of Non-Small Cell Lung Cancer Patients Receiving Preoperative Chemo- or Chemoradiotherapy Followed by Surgery.

Authors:  Ryu Kanzaki; Naoko Ose; Tomohiro Kawamura; Soichiro Funaki; Yasushi Shintani; Masato Minami; Nobuyuki Takakura; Meinoshin Okumura
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

5.  Perioperative outcomes and lymph node assessment after induction therapy in patients with clinical N1 or N2 non-small cell lung cancer.

Authors:  Jessica Glover; Frank O Velez-Cubian; Kavian Toosi; Emily Ng; Carla C Moodie; Joseph R Garrett; Jacques P Fontaine; Eric M Toloza
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

6.  Extended sleeve lobectomy after induction chemoradiotherapy for non-small cell lung cancer.

Authors:  Shinichi Toyooka; Junichi Soh; Hiromasa Yamamoto; Masaomi Yamane; Shigeru Hattori; Kazuhiko Shien; Kentaroh Miyoshi; Seiichiro Sugimoto; Takahiro Oto; Shinichiro Miyoshi
Journal:  Surg Today       Date:  2014-09-12       Impact factor: 2.549

7.  Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer.

Authors:  Hidejiro Torigoe; Junichi Soh; Shuta Tomida; Kei Namba; Hiroki Sato; Kuniaki Katsui; Katsuyuki Hotta; Kazuhiko Shien; Hiromasa Yamamoto; Masaomi Yamane; Susumu Kanazawa; Katsuyuki Kiura; Shinichiro Miyoshi; Shinichi Toyooka
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

8.  Optimal managements of stage IIIA (N2) non-small cell lung cancer patients: a population-based survival analysis.

Authors:  Zhaofei Pang; Yufan Yang; Nan Ding; Cuicui Huang; Tiehong Zhang; Yang Ni; Jiajun Du; Qi Liu
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

9.  CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.

Authors:  Jiahui Si; Panpan Zhang; Dan Tian; Xing Wang; Yuanyuan Ma; Jianzhi Zhang; Lu Wang; Yue Yang
Journal:  World J Surg Oncol       Date:  2017-01-28       Impact factor: 2.754

10.  Is Surgery after Chemoradiotherapy Feasible in Lung Cancer Patients with Superior Vena Cava Invasion?

Authors:  Hiroki Sato; Junichi Soh; Katsuyuki Hotta; Kuniaki Katsui; Susumu Kanazawa; Katsuyuki Kiura; Shinichi Toyooka
Journal:  Ann Thorac Cardiovasc Surg       Date:  2018-04-20       Impact factor: 1.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.